Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 5/20 | 0.34 |
| ▸ | TTK | P33981 | 2/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | YES1 | P07947 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30340810 | 1.00 | GSK3B (0.46) | GSK3BDYRK1AUSP30WNT1TTK | |
| SCHEMBL23580326 | 0.77 | GSK3B (0.48) | GSK3BDYRK1AUSP30WNT1TTK | |
| SCHEMBL23607512 | 0.77 | DYRK1A (0.49) | GSK3BDYRK1AUSP30WNT1MAP4K1 | |
| SCHEMBL23580531 | 0.76 | MAP4K4 (0.41) | MAP4K1MAPK1 | |
| SCHEMBL30340788 | 0.76 | MAP4K4 (0.41) | MAP4K1MAPK1 | |
| SCHEMBL23580985 | 0.73 | GSK3B (0.46) | GSK3BDYRK1AUSP30WNT1RET | |
| SCHEMBL31600809 | 0.68 | GSK3B (0.51) | GSK3BDYRK1AABL1MAPK1 | |
| SCHEMBL6133162 | 0.67 | ALDH1A1 (0.54) | GSK3BDYRK1A | |
| SCHEMBL20119347 | 0.66 | GSK3B (0.45) | GSK3BDYRK1ARET | |
| SCHEMBL31439308 | 0.65 | GSK3B (0.53) | GSK3BDYRK1AUSP30WNT1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | GSK3B 953/4885DYRK1A 3482/4885USP30 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.